ICE MOOD

Brand	Owner	Address	Description
ICEMOOD	Guangzhou Zhijin E-Commerce Co., Ltd.	Room 6699, 2nd Floor, Zone D, No. 26 Huangcun North Road, Tianhe District Guangzhou 510000 China	ICE MOOD;Boots; Coats; Dresses; Hats; Jeans; Leggings; Pullovers; Pyjamas; Sandals; Scarves; Shapewear; Shoes; Sleepwear; Slippers; Socks; Stockings; Sweaters; T-shirts; Trousers; Underwear; Vests; Belts; Bottoms as clothing for babies, adults, children, women, men; Caps being headwear; Denim jackets; Gloves as clothing; Halloween costumes; Jackets; Outer jackets; Rain boots; Shirts and short-sleeved shirts; Short-sleeved or long-sleeved t-shirts; Skirts and dresses; Sleep masks; Sport shirts; Sports jerseys; Sports shoes; Tops as clothing for babies, adults, children, women, men; Yoga pants; Yoga tops;The wording ICEMOOD has no meaning in a foreign language.;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and/or other clinical therpauetic and/or diagnostic areas.